{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055656","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.120440+00:00","generated_at":"2026-06-02T10:03:24.389160+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"REGENXBIO Q1 net loss $63.3M; RGX-202 selects pivotal dose; cash $380.5M","bullets":["Net loss $63.3M ($1.38 diluted EPS) vs $66.7M ($1.53) YoY; revenue $15.6M, down from $19.1M.","Cash, equivalents and marketable securities $380.5M (up from $314.1M), runway into 2026.","RGX-202 Duchenne: pivotal dose DL2 selected; second patient showed 20.9% microdystrophin expression, 90% CK reduction.","ABBV-RGX-314 DR: positive interim ALTITUDE data; end-of-Phase II meeting FDA Q1 2025; pivotal trial H1 2025.","RGX-121 BLA filing on track for 2024 via accelerated approval; potential Priority Review Voucher."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055656","json":"https://secwatch.observer/filing/0000950170-24-055656.json","markdown":"https://secwatch.observer/filing/0000950170-24-055656.md","text":"https://secwatch.observer/filing/0000950170-24-055656.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000095017024055656/0000950170-24-055656-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000095017024055656/rgnx-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T10:03:24.389160+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"473bb221b0fc7009ef36077f0174115b5151b51b","claim":"REGENXBIO Inc. reported the first quarter ending March 31, 2024 results: revenue $15.6 million.","evidence_excerpt":"and pre-funded warrants completed in March 2024, and was partially offset by cash used to fund operating activities during the first quarter of 2024. Revenues: Revenues were $15.6 million for the three months ended March 31, 2024, compared to $19.1 million for the three months ended March 31, 2023. The decrease was primarily attributable to non-recurring","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000095017024055656/0000950170-24-055656-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ending March 31, 2024"},{"label":"Revenue","value":"$15.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}